Описание
Azithromycin is a weak CYP3A4 inhibitor that can modestly raise loratadine plasma levels; the clinical impact is minimal given loratadine's wide therapeutic index and low cardiac risk.
Механизм
Azithromycin inhibits CYP3A4 to a minor degree, reducing hepatic metabolism of loratadine; azithromycin itself carries a small QT-prolonging potential, creating a theoretical additive cardiac risk.
Клиническое значение
No significant QT changes or adverse events are expected at standard doses in patients without underlying cardiac risk factors.
Тактика ведения
No dose adjustment required; exercise caution in patients with QT prolongation risk factors or electrolyte abnormalities.
Медицинский отказ от ответственности
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.